Cogent Biosciences will present eight posters at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, scheduled for February 27‑March 2, 2026. The posters, slated for display on February 28, 2026 from 9:45 am to 10:45 am ET in Hall A, will highlight expanded results from the Phase 2 SUMMIT trial of bezuclastinib in adults with non‑advanced systemic mastocytosis (NonAdvSM).
The presentation follows the company’s recent FDA Breakthrough Therapy Designation for bezuclastinib in NonAdvSM and the designation for the combination with sunitinib in gastrointestinal stromal tumors (GIST) announced January 26, 2026. Cogent also submitted its New Drug Application for bezuclastinib in NonAdvSM on December 30, 2025 and plans to file the GIST combination NDA in April 2026, positioning the drug for potential market approval in two distinct rare‑disease indications.
The SUMMIT trial data reinforce bezuclastinib’s efficacy and tolerability, supporting its status as a potential best‑in‑class KIT inhibitor for NonAdvSM. “This NDA is the first of three planned submissions for bezuclastinib based on positive clinical data from three pivotal trials completed in 2025 for patients with systemic mastocytosis and GIST. Building on the exceptional results from the SUMMIT trial, this filing moves us closer to delivering an important disease‑modifying therapy to patients with NonAdvSM.” – Andrew Robbins, President and Chief Executive Officer.
Cogent’s pipeline extends beyond bezuclastinib, with programs targeting FGFR2, ErbB2, PI3Kα, KRAS, and JAK2. The company entered 2026 with approximately $900 million in cash, providing a runway through 2028 and supporting planned commercial launches. “We are excited to announce Breakthrough Therapy Designation for bezuclastinib, which highlights the FDA's recognition of the unmet need for patients with NonAdvanced Systemic Mastocytosis and the potential for bezuclastinib to redefine the treatment paradigm for this disease.” – Andrew Robbins.
“We are excited to present additional data from the SUMMIT trial that support our conviction that bezuclastinib will be the best‑in‑class treatment option for patients with nonadvanced systemic mastocytosis.” – Andrew Robbins
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.